Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Shuimu BioSciences
AddedFeb 17, 2024
UpdatedJun 18, 2026
Shuimu BioSciences

Shuimu BioSciences

Shuimu: Leveraging AI and cryo-EM for rapid, precision drug discovery and therapeutic innovation.

HQ
Cambridge, MA, US
Founded
2017
Overview
Compare
Fundraising
Employees
Website

Shuimu BioSciences, founded with a mission to revolutionize drug discovery and therapeutic innovation, leverages cutting-edge cryo-electron microscopy (cryo-EM) and Artificial Intelligence (AI) technologies. The company aims to accelerate the development of novel therapeutics by providing one-stop solutions for structure-based drug discovery. Shuimu's offerings include advanced cryo-EM platforms, proprietary GraFuture technologies, and AI-driven data processing and modeling, targeting the pharmaceutical and biotech sectors.

Notable achievements include the publication of significant research such as the cryo-EM structure of DNA polymerase θ helicase domain in complex with inhibitor novobiocin. Shuimu's impact is marked by its eight 300kV cryo-EMs and its role in advancing precision medicine for challenging diseases. The company’s technological excellence and global leadership position it as a key partner in next-generation drug innovation.

Shuimu BioSciences - Similar Companies

Health Technology Innovations logo

Health Technology Innovations

hti.ai

Empress Therapeutics logo

Empress Therapeutics

empresstx.com

Biosim logo

Biosim

Transition Bio logo

Transition Bio

transitionbio.com

Immunocure Discovery Solutions logo

Immunocure Discovery Solutions

immunocure.us

QuantumBio logo

QuantumBio

quantumbioinc.com

BioMap logo

BioMap

biomap.com

Cryptyx Bioscience logo

Cryptyx Bioscience

Medium Biosciences logo

Medium Biosciences

medium.bio

Parallel Bio logo

Parallel Bio

parallel.bio

DeepCure logo

DeepCure

deepcure.ai

Curi Bio logo

Curi Bio

curibio.com

Superluminal Medicines logo

Superluminal Medicines

superluminalrx.com

Bpgbio logo

Bpgbio

bpgbio.com

DeepBiome Therapeutics logo

DeepBiome Therapeutics

Shuimu BioSciences - Quick Facts

Who are Shuimu BioSciences' competitors?

Companies similar to Shuimu BioSciences include Health Technology Innovations, Empress Therapeutics, Biosim and Transition Bio.

When was Shuimu BioSciences founded?

Shuimu BioSciences was founded in 2017.

Where is Shuimu BioSciences' headquarters located?

Shuimu BioSciences' headquarters is located in Cambridge, MA, US.

When was Shuimu BioSciences' last funding round?

Shuimu BioSciences' most recent funding round was for $25M (USD) in April 2022.

How much has Shuimu BioSciences raised to-date?

As of Apr 3, 2022, Shuimu BioSciences has raised a total of $40M (USD).

How many employees does Shuimu BioSciences have?

Shuimu BioSciences has 75 employees as of Feb 4, 2024.

Shuimu BioSciences - Classification

Industry
  • Professional Service Companies
Ownership
  • Private
Technology
  • AI
  • Cryo-Em
Geographic Exposure
  • Global
Model
  • Platform
Customer
  • Enterprise
Main Product
  • Drug Discovery
Tags
  • AI Operations
  • Biotech
  • Consulting
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software